生命科学资讯
生物技术与制药领域的最新动态
US International Trade Commission to take a closer look at Chinese biotech
Merck cuts more than 150 jobs at new Gardasil vaccine plant in North Carolina
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design
银杏剥离生物安全业务；强生公布早期前列腺癌数据
Ginkgo divests biosecurity arm; J&J's early prostate cancer data
帕德塞夫-凯特鲁达联合疗法在膀胱癌治疗中再传佳音
Padcev-Keytruda combo delivers more positive data in bladder cancer
诺华完成Avidity交易，罕见心脏病业务分拆启动。
Novartis closes Avidity deal as rare heart disease spinout launches
投资者正将资金注入健康保险公司的AI工具。
Investors are pumping money into AI tools for health insurers
诺和诺德的“战略困境”：固守过去或将错失未来
Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
司法部敦促最高法院撤销对希克玛“瘦身标签”案的复审。
DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case
萨雷普塔CEO道格·英格拉姆的意志力遭遇挑战，计划离职。
Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart
FDA借助外部力量调查内部普拉萨德投诉。
FDA probes internal Prasad complaints with outside help
勃林格殷格翰肺癌药物获加速批准用于一线治疗。
Boehringer wins accelerated approval for first-line use of lung cancer drug
参议院听证会引发对罕见病新药FDA相关问题的担忧
Senate hearing raises FDA-related concerns for new rare disease drugs
Viatris计划裁员至多10%，并披露印度工厂火灾事件。
Viatris plans to lay off up to 10% of staff, discloses Indian factory fire
医生为何推荐Grail公司备受争议的癌症检测？
Why did my doctor push Grail’s dubious cancer test?
AtaiBeckley股价因二期a阶段数据下跌；Disc将重新提交罕见病药物申请。
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug
主角退出武田利润分享协议，将获4亿美元现金。
Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
诺华将再建放射性配体工厂；德国加强对格瑞克海默的调查。
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer